Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    Regulatory Relief For Certain Stationary Sources To Promote American Security With Respect To Sterile Medical Equipment (Trump EO Tracker)

    This proclamation addresses the EPA's April 5, 2024 final rule, National Emission Standards for Hazardous Air Pollutants...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Akin
    Akin
  • Article

    Restrictions Governing International Trade In Genetic Resources Enter Into Force

    On 12 October 2014, the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization (‘the Protocol’) entered into international force.
    United StatesFood, Drugs, Healthcare, Life Sciences
WilmerHale
WilmerHale
  • Article

    Royalty Monetizations: The "What, Why, When, Who And How" For Universities, Non-Profit Institutions And Life Sciences Companies

    Are you a university or non-profit who's curious about the ways to unlock the potential of your incoming life sciences product royalty streams? In our comprehensive guide...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley Hoag LLP
    Foley Hoag LLP
  • Article

    Royalty Monetizations: The "What, Why, When, Who And How" For Universities, Non-Profit Institutions And Life Sciences Companies

    Are you a university or non-profit who's curious about the ways to unlock the potential of your incoming life sciences product royalty streams?
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley Hoag LLP
    Foley Hoag LLP
  • Article

    Safer And More Powerful Batteries – Dreamliner And Political

    The Wall Street Journal and other media are reporting that the National Transportation Safety Board is investigating microscopic "dendrite" formation as possible causes for the "dreamliner" lithium ion battery problems.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Sandoz Denosumab BLA Accepted By FDA

    The US FDA has accepted a Biologics License Application (BLA) from Sandoz for a proposed denosumab biosimilar. In its press-release, Sandoz stated that the "application includes all indications...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Sandoz Launches Natalizumab Biosimilar

    On November 17, 2025, Sandoz announced the launch of TYRUKO® (natalizumab-sztn) in the United States as the first and only biosimilar for the treatment of relapsing forms of multiple sclerosis.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Second Judge Grants Temporary Injunction Against Favored Nation Rule

    On December 28, 2020, Judge Vince Chhabria of the US District Court for the Northern District of California joined Judge Catherine Blake of the US District Court of the District of Maryland in...
    United StatesFood, Drugs, Healthcare, Life Sciences
    ArentFox Schiff
    ArentFox Schiff
  • Article

    Senate Bill Would Establish Federal Biotechnology Security Framework

    On January 29, 2026, Senator Tom Cotton (R-AR) introduced the Biosecurity Modernization and Innovation Act of 2026 (S. 3741) to establish a federal biosecurity framework.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Bergeson & Campbell
    Bergeson & Campbell
  • Article

    Senate Subcommittee Will Hold Hearing On Building A Resilient Health Care Future With Biotechnology

    The Senate Finance Subcommittee on Health Care will convene to examine how biotechnology can strengthen America's healthcare infrastructure and address critical challenges in medical innovation. Expert witnesses from leading research institutions and academic medical centers will provide testimony on advancing biotechnology solutions for infectious diseases, antibiotic resistance, and healthcare resilience.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Bergeson & Campbell
    Bergeson & Campbell
  • Article

    Shameless Plug: 2018 DRI Drug And Medical Device Seminar

    The DRI's Drug and Medical Device Committee will present its annual seminar on May 10-11 at the New York Marriott Marquis
    United StatesFood, Drugs, Healthcare, Life Sciences
    Reed Smith
    Reed Smith
  • Article

    Similis Bio And Blau Farmaceutica Enter Into Development And License Agreement For Biosimilars

    On October 25, 2022, JSR Life Sciences and Blau Farmaceutica announced that Similis Bio, JSR Life Sciences's business unit focused on biosimilar development, has signed its first development and license agreement...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    So You Want To Make A Biosimilar: Top Considerations Before BLA Submission

    Developing and successfully commercializing a biosimilar is a complex and expensive process. On September 13, 2023, in the first webinar in Goodwin's 2023 Biosimilars Webinar Series...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Structure Therapeutics – $185.3 Million IPO

    The offering marks the first sizable US life sciences IPO this year.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Cooley LLP
    Cooley LLP
  • Article

    Summary Of Trump Administration Drug Pricing And AKS Rulemakings And Implications For Life Sciences Companies And Health Care Providers

    On Friday, November 20, 2020, 60 calendar days prior to the inauguration of President-Elect Biden, the Trump administration released three rulemakings with significant implications for life sciences companies and healthcare providers.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley Hoag LLP
    Foley Hoag LLP
  • Article

    Sun Pharma Launches ILUMYA® In India

    On December 1, 2025, Sun Pharmaceutical Industries Ltd. ("Sun Pharma") announced the launch of ILUMYA® (tildrakizumab-asmn) in India. ILUMYA® is a humanized monoclonal antibody injection indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Supernus Wins Appeal Against Second Generic Challenger To Oxtellar XR®

    Following an August 6, 2018 oral argument, the United States Court of Appeals for the Federal Circuit on September 6, 2018 unanimously affirmed the District of New Jersey's August 15, 2017 ruling ...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Haug Partners
    Haug Partners
  • Article

    Supreme Court Decides Myriad Case: Synthetic DNA Held Patentable & Implications For Nanotech

    The Supreme Court recently rendered its decision in the landmark Myriad case, holding that naturally occurring DNA segments are not patentable, but synthetic DNA segments are patent eligible based on the patent eligibility requirement of 35 U.S.C.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    Teva And Alvotech's Adalimumab Biosimilar Receives Interchangeable Status At FDA

    On February 23rd, 2024, Alvotech and Teva announced FDA's approval of SIMLANDI (adalimumab-ryvk), the first high-concentration and citrate-free biosimilar interchangeable with Humira...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Texas House Passes Psychedelics Bills Aimed At Expediting Access To Psychedelic Therapy

    Although the bill still needs to pass the Texas Senate and ultimately be approved by the Senate, the Lone Star State has thrown down a significant marker in advancing the approval...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Buchanan Ingersoll & Rooney
    Buchanan Ingersoll & Rooney
  • Showing 541–560 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics